95093-99-5

Basic information

• Product Name: (R)-(+)-CARVEDILOL
• Synonyms: (+)-1-(9H-CARBAZOL-4-YLOXY)-3-[[2-(2-METHOXYPHENOXY)ETHYL]AMINO]-2-PROPANOL;(R)-(+)-CARVEDILOL;(R)-Carvedilo;2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2R)-;2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (R)-;(2R)-1-(9H-Carbazole-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propane-2-ol;(R)-1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol;[R,(+)]-1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
• CAS NO: 95093-99-5
• Molecular Formula: C₂₄H₂₆N₂O₄
• Molecular Weight: 406.47
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics;Heterocycles;API
• Mol File: 95093-99-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 114-115°C
• Boiling Point: 655.2 °C at 760 mmHg
• Flash Point: 350.1 °C
• Appearance: /
• Density: 1.25 g/cm³
• Vapor Pressure: 4.63E-18mmHg at 25°C
• Refractive Index: 1.657
• Storage Temp.: -20°C Freezer
• PKA: 13.90±0.20(Predicted)
• CAS DataBase Reference: (R)-(+)-CARVEDILOL(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(+)-CARVEDILOL(95093-99-5)
• EPA Substance Registry System: (R)-(+)-CARVEDILOL(95093-99-5)

Safety Data

• Hazardous Substances Data: 95093-99-5(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 95093-99-5 differently. You can refer to the following data:
1. (R)-(+)-Carvedilol is the optically active isomer of Carvedilol, a nonselective -adrenergic blocker with a1-blocking activity. An antihypertensive used in the treatment of congestive heart failure
2. The optically active isomer of Carvedilol (C184625), a nonselective ?-adrenergic blocker with a1-blocking activity. An antihypertensive used in the treatment of congestive heart failure.

InChI:InChI=1/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3/t17-/m1/s1

Upstream product

• 293738-17-7 N-[2-(2-methoxyphenoxy)ethyl]acetamide 
• 90-05-1 2-methoxy-phenol 
• 52602-39-8 9H-carbazol-4-ol 
• 95093-96-2 (R)-4-(oxiran-2-ylmethoxy)-9H-carbazole 
• 1836-62-0 2-(2-methoxy-phenoxy)-ethylamine 
• 72956-09-3 carvedilol 
• 591-20-8 3-Bromophenol 
• 95093-95-1 S-(+)-4-(oxiranylmethoxy)-9H-carbazole 
• 180988-02-7 C₂₅H₂₄N₂O₅ 
• 180988-03-8 C₂₅H₂₄N₂O₅ 

Relevant articles and documents

In-situ and one-step preparation of protein film in capillary column for open tubular capillary electrochromatography enantioseparation

In this work, the phase-transitioned BSA (PTB) film using the mild and fast fabrication process adhered to the capillary inner wall uniformly, and the fabricated PTB film-coated capillary column was applied to realize open tubular capillary electrochromatography (OT-CEC) enantioseparation. The enantioseparation ability of PTB film-coated capillary was evaluated with eight pairs of chiral analytes including drugs and neurotransmitters, all achieving good resolution and symmetrical peak shape. For three consecutive runs, the relative standard deviations (RSD) of migration time for intra-day, inter-day, and column-to-column repeatability were in the range of 0.3%–3.5%, 0.2%–4.9% and 2.1%–7.7%, respectively. Moreover, the PTB film-coated capillary column ran continuously over 300 times with high separation efficiency. Therefore, the coating method based on BSA self-assembly supramolecular film can be extended to the preparation of other proteinaceous capillary columns.

Hybridization of β-Adrenergic Agonists and Antagonists Confers G Protein Bias

Starting from the β-adrenoceptor agonist isoprenaline and beta-blocker carvedilol, we designed and synthesized three different chemotypes of agonist/antagonist hybrids. Investigations of ligand-mediated receptor activation using bioluminescence resonance energy transfer biosensors revealed a predominant effect of the aromatic head group on the intrinsic activity of our ligands, as ligands with a carvedilol head group were devoid of agonistic activity. Ligands composed of a catechol head group and an antagonist-like oxypropylene spacer possess significant intrinsic activity for the activation of Gαs, while they only show weak or even no β-arrestin-2 recruitment at both β1- and β2-AR. Molecular dynamics simulations suggest that the difference in G protein efficacy and β-arrestin recruitment of the hybrid (S)-22, the full agonist epinephrine, and the β2-selective, G protein-biased partial agonist salmeterol depends on specific hydrogen bonding between Ser5.46 and Asn6.55, and the aromatic head group of the ligands.

Synthesis of Glycoborine, Glybomine A and B, the Phytoalexin Carbalexin A and the β-Adrenoreceptor Antagonists Carazolol and Carvedilol

We describe a regioselective synthesis of 4- or 5-substituted carbazoles by oxidative cyclisation of meta-oxygen-substituted N-phenylanilines. Using the regiodirecting effect of a pivaloyloxy group, we prepared 4-hydroxycarbazole, a precursor for the enantiospecific synthesis of the β-adrenoreceptor antagonists (?)-(S)-carazolol (5) and (?)-(S)-carvedilol (6). Regioselective palladium(II)-catalysed cyclisation of different diarylamines led to total synthesis of glycoborine (7) and the first total syntheses of the phytoalexin carbalexin A (8), glybomine A (9) and glybomine B (10). For glybomine B (10), a 5-hydroxycarbazole was converted into the corresponding triflate and utilized for introduction of a prenyl substituent.